Business Wire

IL-NEXTSENSE

3.12.2021 16:02:13 CET | Business Wire | Press release

Share
NextSense Emerges to Unlock Brain Health with Key Partners UCB, Heraeus, UC San Diego, and Emory University

NextSense, the foundation of brain health, came out of stealth with an announcement made from the AES (American Epilepsy Society) Annual Meeting in Chicago, where NextSense and its partners are presenting the results of their research on seizure detection to peers in academia and industry for the first time.

NextSense unlocks brain health with real world data insights and practical, scientific wisdom for daily living. Traditional brain health monitoring technology like EEG machines and polysomnograms are too bulky for home use, requiring patients to stay overnight at hospitals or sleep study clinics for observation. The high cost of care and lack of comfort of these devices makes long-term and continuous monitoring nearly impossible. Not only are these data based on a single timeframe, they observe what is anything but an ordinary night’s sleep. And for anyone living with epilepsy, the unpredictability of seizures makes direct observation and high-quality data-gathering exceedingly rare.

The NextSense platform starts with longitudinal EEG data collected at the point of experience with biosensing earbuds that can be worn comfortably at night and as-needed throughout the day. The company envisions combining that data with environmental and behavioral patterns collected from smart devices and timely analysis from its team of neuroscientists to help doctors identify triggers, diagnose certain conditions and tailor treatment and medication recommendations in real-time.

At the AES Annual Meeting, NextSense detailed for the first time its key relationship with biopharma partner UCB. The company also revealed research and IP agreements with both Heraeus and UC San Diego, as well as a multi-dimensional collaboration with researchers at Emory University.

“We believe that technologies that enable earlier detection of seizures and improve the coordination of care for people living with epilepsy complement UCB’s strong heritage in epilepsy and portfolio of medicines,” said Colin Lake, Vice President of Digital Business Transformation for Neurology at UCB. “Being able to access meaningful data that NextSense can provide will allow us to capture insights and solve complex disease questions that will help epilepsy patients on their care journey achieve better outcomes.”

Each pharma and biotech company has partnered with NextSense to study how neurologists can better calibrate and manage treatment plans for epilepsy, sleep, and potentially other CNS disorders, using the company’s platform.

Emory University’s Brain Health Center, led by world-renowned physician-scientist Allan Levey, is the site of multiple NextSense studies and its first two clinical trials.

"We're excited for what this partnership means for both NextSense and Emory Brain Health," said Allan Levey, Founding Director of Goizueta Institute at Emory Brain Health. "Our work alongside Emory's Department of Biomedical Informatics signifies a notable step forward toward chronic ambulatory monitoring of brain physiology via EEG. With their earbuds allowing access for monitoring data over much longer periods of time, the initial findings and foundational work are very promising and showing how their efforts and technology has significant potential to revolutionize the approach to diagnosing and treating many neurological disorders in the future."

“We’ve assembled a dream team of collaborators,” said Jonathan Berent, Founder and CEO of NextSense. “It is a personal and professional thrill to partner with these innovators at the very top of their field. Our partners have worked with us shoulder-to-shoulder to methodically pursue what many people said was impossible. We are beyond excited to begin to show the world what we have achieved, starting with the scientific community at AES.”

NextSense is continuing to enroll participants in clinical trials focused on epilepsy and sleep. Eventually, the company hopes to leverage the long-term data collected to help establish biomarkers for brain health.

“Whether someone is living with epilepsy, struggling to stay alert, or seeking an elusive diagnosis for a neurological condition, we’re offering hope,“ said Jen Dwyer, Medical Director of NextSense. “We see our members from every angle, and we understand their unique pain points. We’re working towards a world where those who suffer from these conditions don’t have to choose between comfort and accuracy. And we’re just getting started.”

About NextSense, Inc.

NextSense is the foundation of a healthy brain.

We unlock brain health with real-world data insights and practical, scientific wisdom for daily living. Whether you are struggling to stay alert, living with something like epilepsy, seeking an elusive diagnosis for a neurological condition, we can help.

We are a passionate team of neuroscientists and venture operators on a mission to catalyze brain health in both science and culture.

To learn more, please visit: www.nextsense.io

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide8.4.2026 18:00:00 CEST | Press release

Part of the Visa Intelligent Commerce portfolio, Intelligent Commerce Connect will enable more ways for agents to pay and merchants to accept agentic transactions in a single integrationCurrently in pilot with select partners including Aldar, AWS, Diddo, Highnote, Mesh, Payabli, Sumvin, and rolling out to more partners this year Visa Inc. (NYSE: V) today unveiled Intelligent Commerce Connect, a new solution that makes it easier for businesses to connect to and participate in AI-powered commerce. Intelligent Commerce Connect acts as a network, protocol, and token vault-agnostic ‘on ramp’ to agentic commerce for agent builders, merchants, and enablers. As consumers increasingly rely on AI agents to make purchases, businesses – whether they are building agents, selling to them, or processing transactions – need a simple way to get started. Intelligent Commerce Connect, part of the Visa Intelligent Commerce portfolio, meets that need. Through a single integration via the Visa Acceptance Pl

Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield Complete the Acquisition of Air Lease Corporation8.4.2026 15:13:00 CEST | Press release

Sumitomo Corporation, SMBC Aviation Capital, Apollo-managed funds (“Apollo”) and Brookfield today announced that they have completed the previously announced acquisition of Air Lease Corporation (“Air Lease”) and have renamed the business Sumisho Air Lease Corporation (“Sumisho Air Lease”). This transformational transaction improves the financial position of the business with long term support and aviation expertise from co-investors Sumitomo Corporation, SMBC Aviation Capital, Apollo and Brookfield. Sumisho Air Lease’s strong foundation as an established aircraft lessor, supported by SMBC Aviation Capital’s industry‑leading capabilities as servicer, creates a platform with the scale and financial strength needed to meet the fast‑changing and increasingly complex requirements of airline customers. Sumisho Air Lease will also benefit from the deep expertise and long-standing commitment that both Sumitomo Corporation and SMBC Aviation Capital bring to the global aviation leasing sector.

Sitetracker Launches Scout, an Agentic AI Platform Purpose-Built for Critical Infrastructure8.4.2026 15:00:00 CEST | Press release

Sitetracker, the leading Asset Lifecycle Management platform for critical infrastructure, today announced the launch of Scout, its new Agentic AI platform designed to help infrastructure owners, operators, and contractors gain deep insights and drive automation within their operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408923336/en/ Scout, ready for real work As your AI analyst and agent, Scout is ready to work on day 1. Scout provides clarity when decisions are forming and momentum when action is required. It surfaces risk, synthesizes information, and helps accelerate execution by connecting data and driving action. Scout creates operational intelligence and turns it into action all in a secure environment that protects data sovereignty. “Our customers are looking to create compounding competitive advantages,” said Giuseppe Incitti, Chief Executive Officer of Sitetracker. “Scout delivers by providing easy t

Westinghouse Hosts Annual VVER Fuel Forum with Customers8.4.2026 15:00:00 CEST | Press release

Westinghouse currently has fuel supply contracts with all the European VVER operators Westinghouse and MVM Paks Nuclear Power Plant (NPP) recently co-hosted the VVER Fuel Forum in Budapest to share insights and plans for the continued deployment of VVER-1000 and VVER-440 fuel in operating reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408646373/en/ Participants to the VVER Fuel Forum Péter János Horváth, CEO of MVM Paks, welcomed all the participants, highlighting that Hungary is ending two decades of single supplier fuel dependency thanks to the agreement recently signed with Westinghouse to supply the VVER-440 NOVA E-6 fuel design. Six customers presented the progress made and positive outcomes achieved in the past years with the introduction of Westinghouse fuel into mixed cores with resident fuel in their reactors: Energoatom has extensive experience with Westinghouse VVER-440 and VVER-1000 fuel, currently u

Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production Enhancers8.4.2026 15:00:00 CEST | Press release

Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs.Virica and FUJIFILM Biosciences will co-develop an off-the-shelf enhancer–media solution to boost AAV yields and process robustness in FUJIFILM Biosciences BalanCD® HEK293 system. Virica Biotech (“Virica”), a cell enhancer company specializing in Viral Sensitizers (VSE™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), under the Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The collaboration will focus on optimizing a VSE™ formulation for FUJIFILM Biosciences BalanCD HEK293 media to support academic and commercial AAV producers globally. AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye